Home Cart Sign in  
Chemical Structure| 572-30-5 Chemical Structure| 572-30-5
Chemical Structure| 572-30-5
Product Citations

Alternative Products

Product Details of Avicularin

CAS No. :572-30-5
Formula : C20H18O11
M.W : 434.35
SMILES Code : O=C1C(O[C@H]2[C@@H]([C@H]([C@H](CO)O2)O)O)=C(C3=CC=C(O)C(O)=C3)OC4=CC(O)=CC(O)=C14
Synonyms :
Quercetin 3-O-α-L-arabinofuranoside
MDL No. :MFCD10566630

Safety of Avicularin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Avicularin

MAPK
pyroptosis

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description Reference
Huh7 cells 100, 50, 25 µg/ml 12, 24, 36, 48 hours Avicularin significantly inhibited Huh7 cell proliferation in a concentration-dependent manner and suppressed cell migration and invasion. PMC6522888
Α-glucosidase 17.05 ± 0.75 μg/mL (IC50) 15 minutes To evaluate the inhibitory activity of Avicularin against α-glucosidase, results showed an IC50 value of 17.05 ± 0.75 μg/mL, indicating significant inhibitory effect. PMC10336581
RAW264.7 macrophages 0, 10, 30, 100, 300, 600 μM 24 hours To evaluate the effect of AL on the viability of RAW264.7 macrophages, results showed that AL at 10-300 μM did not significantly affect cell viability. PMC9838558
RAW 264.7 cells 30, 100 and 300 μM 24 hours To investigate the inhibitory effect of AL on LPS-induced inflammatory response, results showed that AL significantly suppressed the expression of iNOS, COX-2, IL-6, TNF-α and IL-1β. PMC10623517
Bone marrow-derived macrophages (BMMs) 0, 10, 30, 100, 300 μM 5 days To evaluate the effect of AL on the differentiation of BMMs into osteoclasts, results showed that AL significantly inhibited osteoclast formation and activity. PMC9838558
HepG2 cells 10, 20 and 40 μM 6 hours To investigate the inhibitory effect of AL on D-GalN-induced ferroptosis, results showed that AL significantly reduced MDA, ROS and iron levels, increased GSH content, and upregulated the expression of GPX4 and xCT. PMC10623517
MDCK cells 300 to 3.7 µg/mL 72 hours To evaluate the cytotoxicity of the extracts and determine their 50% cytotoxic concentration (CC50). PMC11727637

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description Reference
C57BL/6 mice Ovariectomy (OVX)-induced osteoporosis model Intraperitoneal injection 1.25 mg/kg, 5 mg/kg Every 2 days for 8 weeks To evaluate the protective effect of AL on OVX-induced osteoporosis in mice, results showed that AL significantly increased bone mineral density and reduced the expression of bone resorption marker CTX-1. PMC9838558
ICR mice Pb-induced nerve damage model Intragastric administration 25 mg/kg and 50 mg/kg Once daily for 3 months To evaluate the protective effects of AVL against Pb-induced neurotoxicity, results showed that AVL significantly ameliorated Pb-induced memory impairment, neuroinflammation, ferroptosis, and oxidative stress. PMC11352125
ICR mice Lead-induced liver injury model Intragastric administration 25 mg/kg and 50 mg/kg Once daily for 3 months Evaluate the protective effects of Avi against Pb-induced hepatotoxicity, results showed that Avi significantly alleviated Pb-induced hepatic inflammation, endoplasmic reticulum stress (ERS), and glucose metabolism disorder PMC9697143
Male C57BL/6 mice LPS/D-GalN-induced acute liver failure model Intragastric administration 50 mg/kg Once daily for 3 days To investigate the protective effect of AL on LPS/D-GalN-induced acute liver failure, results showed that AL significantly alleviated hepatic pathological injury, reduced ALT and AST levels, and inhibited inflammatory response and ferroptosis. PMC10623517

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.30mL

0.46mL

0.23mL

11.51mL

2.30mL

1.15mL

23.02mL

4.60mL

2.30mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories